[{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"Vanilloid receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Celularity","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"CYNK-001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Celularity ","highestDevelopmentStatusID":"1","companyTruncated":"Sorrento Therapeutics \/ Celularity "},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"STI-4398","moa":"Spike protein S1 domain","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"STI-6991","moa":"Spike protein S1 domain","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"CYNK-001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Mabpharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"ACE-MAB","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Sorrento Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"COVI-SHIELD","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"SmartPharm Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Gene encoded antibody vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Sorrento","highestDevelopmentStatusID":"1","companyTruncated":"Sorrento Therapeutics \/ Sorrento"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"ACEA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Abivertinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Sorrento","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Sorrento"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"STI-1499","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"STI-4398","moa":"Spike protein S1 domain","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"T-VIVA-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"SmartPharm Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"STI-1499","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Sorrento","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Sorrento"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Abivertinib","moa":"BTK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"STI-1499","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"SmartPharm Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"STI-2020dna","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"STI-1499","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"BioSig Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Merimepodib","moa":"IMPDH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Salicyn-30","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"SP-102","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Abivertinib","moa":"BTK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"COVI-AMG","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"COVI-AMG","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"STI-2099","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"STI-2020","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Aardvark Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Mount Sinai Health System","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Neutralizing antibody cocktail","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Mount Sinai Health System","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Mount Sinai Health System"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"STI-6643","moa":"CD47","graph1":"Oncology","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"ACEA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Merger","leadProduct":"Abivertinib","moa":"TYK","graph1":"Oncology","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Sorrento","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Sorrento"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"STI-3031","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Adipose-derived mesenchymal stem cells","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"ACEA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Abivertinib","moa":"TYK","graph1":"Oncology","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Sorrento","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Sorrento"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Ipilimumab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Sorrento Therapeutics \/ Sorrento","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Sorrento"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"STI-2099","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"NAMRU-3","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"STI-2020","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ NAMRU-3","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ NAMRU-3"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Lee Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sorrento Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"The Texas A&M University System","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"MPI8","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sorrento Therapeutics \/ The Texas A&M University System","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ The Texas A&M University System"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Etanercept","moa":"TNF alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"SKB264","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra Articular Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"STI-9199","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Omicron mRNA Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Scilex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Prefilled Syringe For Epidural","sponsorNew":"Sorrento Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"STI-9167","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"STI-9199","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Lee Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PDL-1","graph1":"Oncology","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sorrento Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Abivertinib","moa":"TYK","graph1":"Oncology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NX-2127","moa":"SARS-CoV-2 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NX-2127","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"STI-1558","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NX-2127","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Abivertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"STI-9167","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NX-2127","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"4P Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Etanercept","moa":"TNF","graph1":"Immunology","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sorrento Therapeutics \/ 4P Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ 4P Therapeutics"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"STI-1558","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IMC-001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"STI-1557","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"STI-1558","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Olgotrelvir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Abivertinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Olgotrelvir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lidocaine","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Sorrento Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
